Dakshidin Corporatio

PINK:DKSC USA Drug Manufacturers - Specialty & Generic
Market Cap
$1.77 Million
Market Cap Rank
#50900 Global
#15620 in USA
Share Price
$0.00
Change (1 day)
+0.00%
52-Week Range
$0.00 - $0.00
All Time High
$0.01
About

Dakshidin Corporation, Inc., through its subsidiaries, operates as a CBD/cannabis-based medical product company. It cultivates cannabis; and operates an online sales portal for CBD products. The company also manages distribution channel programs in the retail distribution, reselling, and direct sales market segments. Dakshidin Corporation, Inc. was formerly known as Avrada, Inc. and changed its n… Read more

Dakshidin Corporatio (DKSC) - Net Assets

Latest net assets as of September 2024: $6.79K USD

Based on the latest financial reports, Dakshidin Corporatio (DKSC) has net assets worth $6.79K USD as of September 2024.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($415.47K) and total liabilities ($408.67K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets $6.79K
% of Total Assets 1.64%
Annual Growth Rate -34.05%
5-Year Change -96.45%
10-Year Change -94.47%
Growth Volatility 155.46

Dakshidin Corporatio - Net Assets Trend (2016–2024)

This chart illustrates how Dakshidin Corporatio's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Dakshidin Corporatio (2016–2024)

The table below shows the annual net assets of Dakshidin Corporatio from 2016 to 2024.

Year Net Assets Change
2024-03-31 $6.79K 0.00%
2023-12-31 $6.79K -72.29%
2023-03-31 $24.51K 0.00%
2022-12-31 $24.51K -87.21%
2022-03-31 $191.61K 0.00%
2021-12-31 $191.61K +35.15%
2021-03-31 $141.78K 0.00%
2020-12-31 $141.78K +502.56%
2019-12-31 $23.53K -80.85%
2018-12-31 $122.88K -9.98%
2017-12-31 $136.50K -1.66%
2016-12-31 $138.81K --

Equity Component Analysis

This analysis shows how different components contribute to Dakshidin Corporatio's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 85750600.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (March 2024)

Component Amount Percentage
Common Stock $2.91 Million 42770.60%
Total Equity $6.79K 100.00%

Dakshidin Corporatio Competitors by Market Cap

The table below lists competitors of Dakshidin Corporatio ranked by their market capitalization.

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Dakshidin Corporatio's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 6,793 to 6,793, a change of 0 (0.0%).
  • Net loss of 17,720 reduced equity.
  • Other factors increased equity by 17,720.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income $-17.72K -260.86%
Other Changes $17.72K +260.86%
Total Change $- 0.00%

Book Value vs Market Value Analysis

This analysis compares Dakshidin Corporatio's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 196.66x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2013-12-31 $0.00 $0.00 x
2016-12-31 $0.00 $0.00 x
2017-12-31 $0.00 $0.00 x
2018-12-31 $0.00 $0.00 x
2019-12-31 $0.00 $0.00 x
2020-12-31 $0.00 $0.00 x
2021-03-31 $0.00 $0.00 x
2021-12-31 $0.00 $0.00 x
2022-03-31 $0.00 $0.00 x
2022-12-31 $0.00 $0.00 x
2023-03-31 $0.00 $0.00 x
2023-12-31 $0.00 $0.00 x
2024-03-31 $0.00 $0.00 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Dakshidin Corporatio utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -260.86%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 0.00%
  • • Asset Turnover: 0.00x
  • • Equity Multiplier: 61.16x
  • Recent ROE (-260.86%) is below the historical average (-194.42%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2011 0.00% 0.00% 0.00x 0.00x $-4.12K
2012 0.00% 0.00% 0.00x 0.00x $-3.58K
2013 0.00% 0.00% 0.00x 0.00x $-131.41K
2016 -1.58% 0.00% 0.00x 2.59x $-16.08K
2017 -1.69% 0.00% 0.00x 2.63x $-15.95K
2018 -11.09% 0.00% 0.00x 2.93x $-25.91K
2019 -779.45% -961.85% 0.04x 20.91x $-185.75K
2020 -5.56% -3.78% 0.42x 3.49x $-22.06K
2021 -5.56% -3.78% 0.42x 3.49x $-22.06K
2021 -113.17% -8743.43% 0.00x 3.26x $-236.00K
2022 -113.17% -8743.43% 0.00x 3.26x $-236.00K
2022 -681.64% 0.00% 0.00x 21.71x $-169.54K
2023 -681.64% 0.00% 0.00x 21.71x $-169.54K
2023 -260.86% 0.00% 0.00x 61.16x $-18.40K
2024 -260.86% 0.00% 0.00x 61.16x $-18.40K

Industry Comparison

This section compares Dakshidin Corporatio's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $548,450,613
  • Average return on equity (ROE) among peers: -450.37%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Dakshidin Corporatio (DKSC) $6.79K 0.00% 60.16x $3.97
Ascend Wellness Holdings Inc (AAWH) $142.87 Million -33.75% 5.44x $48.90 Million
AB Science S.A (ABSCF) $10.73 Million -252.65% 3.71x $39.89 Million
Alterola Biotech Inc (ABTI) $4.85K -2005.32% 0.49x $603.58K
Aurora Cannabis Inc (ACB) $2.04 Billion -34.08% 0.34x $199.15 Million
Acreage Holdings Inc (ACRDF) $204.27 Million -30.85% 1.41x $13.48K
Acura Pharmaceuticals Inc (ACUR) $7.90 Million -63.15% 1.15x $13.20K
Agra Ventures Ltd. (AGFAF) $1.51 Million -44.22% 0.06x $298.23K
Allergy Therapeutics plc (AGYTF) $2.07 Million -2084.75% 31.32x $25.30 Million
Aida Pharmaceuticals Inc (AIDA) $6.67 Million 24.51% 2.78x $1.80
Adcock Ingram Holdings Limited (AIHLF) $3.07 Billion 20.55% 0.55x $85.61 Million